Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)

Psychotropic-related weight gain is a common concern among patients with bipolar disorder
(BD). This concern affects an individual's satisfaction with treatment and may lead to
reduced adherence and illness relapse. Patient-focused care is attentive to patient concerns
while at the same time utilizing evidence-based treatments. Ziprasidone is currently FDA
approved for the maintenance treatment of BD. Ziprasidone may be associated with less weight
gain compared to some alternative BD maintenance treatments. The proposed project will
evaluate how switching to ziprasidone may affect patient adherence, drug attitudes,
satisfaction with care and clinical outcomes (psychiatric symptoms, functional status,
weight) among BD patients concerned with weight gain.